Rajesh P Ringe
Overview
Explore the profile of Rajesh P Ringe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
770
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jitender , Vikram Kumar B, Singh S, Verma G, Kumar R, Mishra P, et al.
Vaccine
. 2024 Jul;
42(20):126099.
PMID: 38981743
Numerous vaccine candidates have emerged in the fight against SARS-CoV-2, yet the challenges posed by viral evolution and the evasion of vaccine-induced immunity persist. The development of broadly protective vaccines...
2.
Khan M, Jakob V, Singh R, Rajmani R, Kumar S, Lemoine C, et al.
Pharmaceutics
. 2023 Dec;
15(12).
PMID: 38140101
Currently deployed SARS-CoV-2 vaccines all require storage at refrigerated or sub-zero temperatures. We demonstrate that after month-long incubation at 37 °C, solubilization, and formulation with squalene-in-water emulsion adjuvant, a stabilized...
3.
Ringe R, Colin P, Ozorowski G, Allen J, Yasmeen A, Seabright G, et al.
PLoS Pathog
. 2023 Oct;
19(10):e1011601.
PMID: 37903160
Neutralizing antibodies (NAbs) to multiple epitopes on the HIV-1-envelope glycoprotein (Env) have been isolated from infected persons. The potency of NAbs is measured more often than the size of the...
4.
Mittal N, Kumar S, Rajmani R, Singh R, Lemoine C, Jakob V, et al.
NPJ Vaccines
. 2023 Oct;
8(1):161.
PMID: 37880298
With the rapid emergence of variants of concern (VOC), the efficacy of currently licensed vaccines has reduced drastically. VOC mutations largely occur in the S1 subunit of Spike. The S2...
5.
Kumar S, Delipan R, Chakraborty D, Kanjo K, Singh R, Singh N, et al.
J Virol
. 2023 Oct;
97(11):e0092223.
PMID: 37861334
The Omicron subvariants have substantially evaded host-neutralizing antibodies and adopted an endosomal route of entry. The virus has acquired several mutations in the receptor binding domain and N-terminal domain of...
6.
Kumar A, Loharch S, Kumar S, Ringe R, Parkesh R
Comput Struct Biotechnol J
. 2023 Sep;
21:4408.
PMID: 37701017
[This corrects the article DOI: 10.1016/j.csbj.2020.12.028.].
7.
Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization
Colin P, Ringe R, Yasmeen A, Ozorowski G, Ketas T, Lee W, et al.
Retrovirology
. 2023 May;
20(1):9.
PMID: 37244989
Background: Neutralizing antibodies (NAbs) protect against HIV-1 acquisition in animal models and show promise in treatment of infection. They act by binding to the viral envelope glycoprotein (Env), thereby blocking...
8.
Kumar N, Taily I, Singh C, Kumar S, Rajmani R, Chakraborty D, et al.
PLoS Pathog
. 2023 May;
19(5):e1011358.
PMID: 37126530
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A virus (IAV) poses enormous challenge in the development of broad-spectrum antivirals that are effective against the existing...
9.
Garg H, Ringe R, Das S, Parkash S, Thakur B, Delipan R, et al.
Pathogens
. 2023 Mar;
12(3).
PMID: 36986341
The World Health Organization (WHO) declared in May 2021 that SARS-CoV-2 is transmitted not only by close contact with infectious respiratory fluids from infected people or contaminated materials but also...
10.
Singh S, Sharma D, Singh C, Kumar S, Singh P, Sharma A, et al.
J Appl Microbiol
. 2023 Mar;
134(3).
PMID: 36914211
Aim: This study was aimed to determine antimicrobial and antiviral activity of a novel lanthipeptide from a Brevibacillus sp. for disinfectant application. Methods And Results: The antimicrobial peptide (AMP) was...